TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06075147

Intervention type: DRUG
Intervention: Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Description: Following the manner of observational study, no intervention will be provided in the study. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and follows approved clinical guidelines.

Intervention type: DRUG
Intervention: Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Description: Following the manner of observational study, no intervention will be provided in the study. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and follows approved clinical guidelines.

Intervention type: DRUG
Intervention: Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Description: Following the manner of observational study, no intervention will be provided in the study. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and follows approved clinical guidelines.

Intervention type: DRUG
Intervention: Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Description: Following the manner of observational study, no intervention will be provided in the study. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and follows approved clinical guidelines.
Study: NCT05143840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Potent tyrosine kinase inhibitor that displays anti-tumor activity by specifically targeting the ABL myristate-binding pocket (STAMP).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascimininb + Nilotinib
Description: For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of nilotinib 300mg, once daily, with the goal of attaining MR4.5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib + Imatinib
Description: For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of imatinib 300mg, once daily, with the goal of attaining MR4.5.
Study: NCT05487040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 (nirmatrelvir)/ritonavir
Description: Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 (nirmatrelvir)/ritonavir
Description: Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
Study: NCT05467696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: For each period, subjects will be dosed with CTP-543 12 mg (1 x 12 mg tablet)
Study: NCT05189756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg
Description: Encapsulated capsule of aprepitant 80mg to make it look alike to the placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated placebo capsules for optical, acoustical and haptic blinding.
Study: NCT05563805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based physical activity intervention
Description: The V-RATE intervention will be delivered through a 360-degree non-mobilized treadmill in a university clinical laboratory for 6-8-weeks (1-2 days/week, 30 minutes/session) totaling 6 sessions. The V-RATE program will be focused on creating a safe and immersive environment supportive of physical activity. The treadmill enables an individual can walk and run at self-paced speed, moving in 360-degrees (i.e., forwards, sideways, and backwards) without risk of falling. The core feature of the self-paced treadmill is a concave walking platform with an adjustable waist hardness that enables a safe, smooth, natural gait while adults with elevated BMI engage in an immersive walking and running motion. During the V-RATE intervention, participants will self-pace their locomotor action (walking/running/bending/ jumping) while they wear the VR headset and experience immersive VR adventure games using the Omniverse VR system.
Study: NCT06407869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Progressive Strength Training
Description: The Functional Progressive Resistance Exercise (FPRE) protocol is designed to improve functional strength through structured workouts. It begins with a 3-minute warmup involving stretching and range of motion exercises, followed by progressively intense sit-to-stand exercises over six weeks. Participants also perform half-kneeling, standing up, and side-step-up exercises, with 20 minutes of total activity and rest intervals. The session ends with a 2-minute cooldown. Weights are gradually increased up to 15 times the initial load, with a minimum of one-minute rest between sets. The regimen is tailored through trial and error to find the maximum load participants can effectively manage.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: conventional physical therapy techniques will be applied
Study: NCT05143840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib + Dasatinib
Description: For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of dasatinib 50mg, once daily, with the goal of attaining MR4.5.
Study: NCT05688111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: Active group will receive 1gm Tranexamic acid 12 hourly for 48 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose water 5%
Description: Placebo group 30ml will be received 12 hourly for 48 hours
Study: NCT05724108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triapine
Description: Given PO
Study: NCT05526560

Intervention type: DEVICE
Intervention: MITRIS RESILIA Mitral Valve, Model 11400M
Description: Replacement of mitral valve with MITRIS RESLIA Mitral Valve
Study: NCT04342962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tagraxofusp
Description: Tagraxofusp is provided as an intravenous (IV) injectable and administered as a 15-minute IV infusion. Cycle 1 will include a 2-day dosing period for the first 3 enrolled patients (Days 1-2), a 2-day plus an optional 3rd day for patients 4-6 (Days 1-2 + Day 3 if patient meets criteria for continued dosing) and a 3-day dosing period for patients 7 and beyond (Days 1-3). Cycle 2 and beyond will include a 5-day dosing period for all patients (Days 1-5). In all cycles and schedules, dose delays up to Day 10 of each cycle will be allowed for resolution of toxicities.
Study: NCT05559580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenciguat (BI 685509)
Description: Avenciguat (BI 685509)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06562348

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients will be offered palliative systemic treatment according to standard of care. Response evaluation will be performed with the imaging-based RECIST according to standard guidelines. Treatment pauses according to institutional guidelines. Blood samples will be analyzed retrospectively to evaluate ctDNA.
Study: NCT04818398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6016a
Description: DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6016a
Description: DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6016a
Description: DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6016a
Description: DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
Study: NCT06562348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ctDNA-RECIST guided palliative systemic treatment
Description: Patients are offered palliative systemic treatment according to standard of care. Response evaluation will be performed using ctDNA-RECIST.~ctDNA is measured before start of treatment. If the baseline sample is ctDNA negative the patient is transferred to an observational cohort, and sampling procedures continues as in the standard arm. If the baseline sample is ctDNA positive the patient continues in the ctDNA-RECIST guided arm. Treatment response is evaluated according to ctDNA-RECIST, and further sampling follows a predefined decision schedule.
Study: NCT04919408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone survey
Description: telephone survey with a questionnaire to assess pain at 3 months and then 6 months after their cesarean section
Study: NCT05041647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25:1 CBD/THC
Description: * 1 dose (1 mL) of HIGH CBD~* 50 mg/ml CBD and 2 mg/ ml THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5:1 CBD/THC
Description: * 1 dose (1 mL) of LOW CBD~* 10 mg/ml CBD and 2 mg/ ml THC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * 1 dose (1 mL) of PLACEBO~* No active ingredients
Study: NCT06361056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: All participants will complete a brief questionnaire.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth app
Description: Eighty Black women with newly diagnosed breast cancer (inclusive of all stages) and who have access to a mobile device or computer will be recruited to the study intervention.
Study: NCT06235749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Gluconate 10%
Description: Administration of Calcium Gluconate 10% IV following umbilical cord clamping

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride 0.9%
Description: Administration of sodium chloride 0.9% IV following umbilical cord clamping
Study: NCT04818398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6016a
Description: DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6016a
Description: DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
Study: NCT05319210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venous catheter application
Description: To examine the effect of virtual reality glasses and buzzy application on pain management during venous catheter insertion in children.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venous catheter application
Description: To examine the effect of virtual reality glasses and buzzy application on pain management during venous catheter insertion in children.
Study: NCT06349174

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoscopic lung volume reduction surgery using endobronchial valve
Description: The patients would undergo bronchoscopic lung volume reduction surgery using the self developed endobronchial valve.
Study: NCT06634277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NavSTAR (Philly adaptation)
Description: Patient Navigation
Study: NCT06633107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac、rehabilitation、exercise
Description: Routine cardiac rehabilitation treatment + corresponding rehabilitation exercise therapy prescription according to the condition: (1) slow walking + stairs climbing + standing aerobic exercise for patients with cardiac function level I; Grade II patients should take slow walking + standing aerobics; Grade III patients undergo bedside chair aerobics; Class IV aerobic exercises on bed.~After discharge aerobic exercise with the help of community exercise equipment. The duration is gradually increased from 10-20min to 30-40min each time; Gradually increase the intensity from 55% to 60% of the maximum heart rate and not exceed 85% (maximum heart rate (times / min) = 220 - age (years)); The frequency gradually increased from 3 days/week to 5 days/week
Study: NCT06634056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo orally three times a day and another placebo orally two times a day on day one of radiotherapy and continue treatment for 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: α-Tocopherol
Description: Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.
Study: NCT06778057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: Acuvue® Oasys MAX 1-Day daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: Acuvue® Oasys MAX 1-Day daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: Acuvue® Oasys MAX 1-Day daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: Acuvue® Oasys MAX 1-Day daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: Acuvue® Oasys MAX 1-Day daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: Acuvue® Oasys MAX 1-Day daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: Dailies Total 1 daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: Dailies Total 1 daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: Dailies Total 1 daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: Dailies Total 1 daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: Dailies Total 1 daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: Dailies Total 1 daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: Clariti 1-Day daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: Clariti 1-Day daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: Clariti 1-Day daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: Clariti 1-Day daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: Clariti 1-Day daily disposable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: Clariti 1-Day daily disposable contact lenses
Study: NCT06779604

Intervention type: PROCEDURE
Intervention: Infraclavicular Block with Dexmedetomidine and Dexamethasone
Description: Infraclavicular block with Dexmedetomidine and Dexamethasone was performed at least 30 min before the start of the operation. The patient was positioned in a supine position arms at the sides or in 90 degree abduction, head turned to the other side. Infraclavicular block was performed with the lateral sagittal technique, while the USG probe was placed under the clavicle and medial to the coracoid process, providing a brachial plexus image in the form of a hyperechoic outer ring and hypoechoic circles, like a classic honeycomb image. A local anesthetic mixture was injected with a 100 mm block needle with negative aspiration and its spread in tissue planes was observed.~If the VAS score was 3 or above, tramadol 1 mg kg-1 was administered as an analgesic drug.

Intervention type: PROCEDURE
Intervention: Infraclavicular Block with Dexmedetomidine and Dexamethasone
Description: Infraclavicular block with Dexmedetomidine and Dexamethasone was performed at least 30 min before the start of the operation. The patient was positioned in a supine position arms at the sides or in 90 degree abduction, head turned to the other side. Infraclavicular block was performed with the lateral sagittal technique, while the USG probe was placed under the clavicle and medial to the coracoid process, providing a brachial plexus image in the form of a hyperechoic outer ring and hypoechoic circles, like a classic honeycomb image. A local anesthetic mixture was injected with a 100 mm block needle with negative aspiration and its spread in tissue planes was observed.~If the VAS score was 3 or above, tramadol 1 mg kg-1 was administered as an analgesic drug.
Study: NCT06777771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reformer pilates exercises
Description: The reformer pilates exercises session will start with 5 minutes of warm-up exercises, continue with resistance exercises for 20 minutes, and end with 5 minutes of cool-down exercises. The springs of the reformer pilates device will be adjusted to create mild fatigue in the first week and will be gradually increased to create moderate fatigue in the following weeks. Reformer pilates sessions will consist of 15-20 different exercises with 12-15 repetitions, including all major muscle groups. These sessions will also include exercises that strengthen the pelvic floor muscles. Reformer pilates sessions will be applied twice a week for 6 weeks, a total of 12 sessions. Apart from this, they will be asked to walk for at least 30 minutes a day, at least 3 days a week.
Study: NCT06779461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnesium Microspheres
Description: Biodegradable Magnesium Embolic Microspheres

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cTACE
Description: cTACE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cTACE
Description: cTACE
Study: NCT06779266

Intervention type: PROCEDURE
Intervention: Suturing
Description: Endoscopic Suturing is a technique of the wound closure after advanced endoscopic third-space resections in the upper and lower gastrointestinal tract. In this technique, the needle is held on the opposite side from the tip with the needle holder. The needle is pierced perpendicularly into the tissue at the side of the wound with an appropriate margin, then driven through the tissue with rotation and grasped at the bottom of the defect. The same steps are repeated from the middle of the wound to create a symmetrical structure.

Intervention type: PROCEDURE
Intervention: Clipping
Description: Clipping is a technique of the wound closure after advanced endoscopic third-space resections I the upper and lower gastrointestinal tract. In this technique, the through-the-scope clips are delivered to the site through the working canal. The arms of the clip are properly put on the both sides of the defect and the clip is closed to seal the margins. The procedure may be repeated along the resection site for complete closure.

Intervention type: PROCEDURE
Intervention: No closure
Description: The resection site after endoscopic submucosal dissection was left open, without additional closure.
Study: NCT06778031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: SHR-1316.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068
Description: SHR-8068.
Study: NCT06779669

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire CAM
Description: Selected patients will answer a questionnaire about their practice and habits with regard to alternative and complementary medicines. Of these patients, 12 will also complete an additional qualitative questionnaire.
Study: NCT06777706

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: QD (Qing Dai)
Description: Children age 4 years to 17.9 years with mild to moderate UC will receive QD and dosing will be stratified based on body weight at time of enrollment.
Study: NCT04202406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen and codeine and caffeine
Description: The patient will receive pretreatment oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine 1 hour before treatment.
Study: NCT06778837

Intervention type: DEVICE
Intervention: Wearable devices to detect lymphedema
Description: All participants will undergo measurement of the upper extremities to test the validity and safety of wearable sensors to measure lymphedema.
Study: NCT06778928

Intervention type: PROCEDURE
Intervention: laparoscopic cholecystectomy
Description: Posterior wall sparing of laparoscopic cholecystectomy in cirrhotic patients
Study: NCT04202406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: The patient will receive pretreatment oral single dose of 1000mg acetaminophen alone 1 hour before treatment.
Study: NCT06779383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates mat exercises
Description: The Pilates exercises were performed on mats. The functional performance on one-leg stance (OLS), five-times-sit-to-stand (STS) and 6-min walk (6 MW) tests was evaluated before and after the 12-week Pilates training or control follow-up period.